Oculis and Accure Therapeutics have agreed to terms for Oculis to license ACT-01, which is under investigation for the prevention of damage to the optic nerve and retina, according to a press release. ACT-01, which will be renamed OCS-05, “is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models […]

Recently published findings from a phase 1 clinical trial (NCT03298672) of fosgonimeton (Athira Pharma) show that the treatment was safe and well tolerated in patients with Alzheimer disease (AD). These results add support to the development of the treatment, previously known as ATH-1017, as a novel therapeutic for people with AD and dementia.1,2 Investigators included […]

As humans, we are allowed a lot of room to make mistakes. After all, this is pretty much how we learn and grow over time, right? Now, while that’s accurate, we, at the same time, can’t really skirt past some obligations in play, a notable one being our obligation to move forward under all circumstances. […]